SG11201806322QA - Maytansinoid derivatives, conjugates thereof, and methods of use - Google Patents

Maytansinoid derivatives, conjugates thereof, and methods of use

Info

Publication number
SG11201806322QA
SG11201806322QA SG11201806322QA SG11201806322QA SG11201806322QA SG 11201806322Q A SG11201806322Q A SG 11201806322QA SG 11201806322Q A SG11201806322Q A SG 11201806322QA SG 11201806322Q A SG11201806322Q A SG 11201806322QA SG 11201806322Q A SG11201806322Q A SG 11201806322QA
Authority
SG
Singapore
Prior art keywords
international
rule
pct
applicant
conjugates
Prior art date
Application number
SG11201806322QA
Other languages
English (en)
Inventor
Thomas Nittoli
Thomas P Markotan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201806322QA publication Critical patent/SG11201806322QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
SG11201806322QA 2016-01-25 2017-01-24 Maytansinoid derivatives, conjugates thereof, and methods of use SG11201806322QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286858P 2016-01-25 2016-01-25
PCT/US2017/014782 WO2017132173A1 (fr) 2016-01-25 2017-01-24 Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201806322QA true SG11201806322QA (en) 2018-08-30

Family

ID=57995285

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806322QA SG11201806322QA (en) 2016-01-25 2017-01-24 Maytansinoid derivatives, conjugates thereof, and methods of use

Country Status (20)

Country Link
US (4) US9950076B2 (fr)
EP (1) EP3408271B1 (fr)
JP (1) JP6934010B2 (fr)
KR (1) KR20180099892A (fr)
CN (2) CN114478801A (fr)
AU (1) AU2017211120C1 (fr)
BR (1) BR112018014759B1 (fr)
CA (1) CA3011440A1 (fr)
CL (1) CL2018002012A1 (fr)
CO (1) CO2018008761A2 (fr)
EA (1) EA039072B9 (fr)
HK (1) HK1257219A1 (fr)
IL (1) IL260744B (fr)
MA (1) MA43094B1 (fr)
MX (1) MX2018008987A (fr)
MY (1) MY198605A (fr)
PH (1) PH12018501589A1 (fr)
SG (1) SG11201806322QA (fr)
WO (1) WO2017132173A1 (fr)
ZA (1) ZA201804593B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
WO2015031396A1 (fr) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des diastéréomères macrolides, leurs procédés de synthèse et leurs utilisations thérapeutiques
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
BR112018014759B1 (pt) * 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
CA3097711A1 (fr) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Anticorps et molecules de liaison a l'antigene bispecifiques se liant a her2 et/ou aplp2, conjugues et utilisations associees
CA3100021A1 (fr) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugues et leurs utilisations
US11666658B2 (en) 2018-12-21 2023-06-06 Regeneran Pharmaceuticals, Inc. Rifamycin analogs and antibody-drug conjugates thereof
KR20210130755A (ko) 2019-02-21 2021-11-01 리제너론 파마슈티칼스 인코포레이티드 항-met 항체 및 met에 결합하는 이중특이적 항원 결합 분자를 사용하여 안구암을 치료하는 방법
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
MX2022005903A (es) 2019-11-15 2022-12-13 Seagen Inc Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2.
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2 and methods of using them
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
IL309173A (en) 2020-07-13 2024-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
AU2021339892A1 (en) 2020-09-14 2023-04-27 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
CN116406379A (zh) 2020-10-22 2023-07-07 瑞泽恩制药公司 抗fgfr2抗体和其使用方法
AU2021377185A1 (en) 2020-11-10 2023-06-08 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20230330254A1 (en) 2022-03-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof
CN116239607B (zh) * 2023-01-04 2024-04-09 山东大学 一种美登素衍生物及其生物合成方法与应用
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2357006B1 (fr) * 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
US7989595B2 (en) 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT1912677E (pt) 2005-06-20 2013-12-23 Psma Dev Company L L C Conjugados de anticorpos contra psma-fármaco
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2061814B1 (fr) 2006-10-27 2012-06-06 Genentech, Inc. Anticorps et immunoconjugues, et leurs utilisations
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2144628B1 (fr) 2007-05-08 2012-10-17 Genentech, Inc. Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
WO2008153744A2 (fr) 2007-05-23 2008-12-18 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
EP3692988A3 (fr) 2008-03-18 2020-10-14 Genentech, Inc. Combinaisons d'un conjugué de médicament-anticorps anti-her2 et 5-fu, anticorps anti-vegf, carboplatin ou abt869 et procédés d'utilisation
EP2276506A4 (fr) 2008-04-30 2014-05-07 Immunogen Inc Conjugués puissants et coupleurs hydrophiles
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2889624B1 (fr) 2009-08-10 2018-10-03 UCL Business PLC Liaison covalente réversible de molécules fonctionnelles
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012028579A1 (fr) 2010-09-01 2012-03-08 Bayer Cropscience Ag Amides de l'acide n-(tétrazol-5-yl)- et n-(triazol-5-yl)arylcarboxylique, et leur utilisation comme herbicides
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
BR112013010853A2 (pt) * 2010-11-03 2016-08-16 Immunogen Inc "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes"
US20160151505A1 (en) 2011-05-16 2016-06-02 Koninklijke Philips N.V. Bio-orthogonal drug activation
EP3170821B1 (fr) 2011-05-27 2021-09-15 Ambrx, Inc. Compositions contenant, procédés impliquant, et utilisations d'acides aminés non naturels dérivés de la dolastatine liée
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9289512B2 (en) * 2011-06-21 2016-03-22 Immunogen, Inc. Maytansinoid derivatives with peptide linker and conjugates thereof
EP2753178B1 (fr) 2011-10-14 2017-12-06 Seattle Genetics, Inc. Pyrrolobenzodiazépines et conjugués ciblés
MX341523B (es) 2011-10-14 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas.
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EA029046B1 (ru) 2011-10-14 2018-02-28 Медимьюн Лимитед Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
AU2012348017A1 (en) 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
IN2014DN10428A (fr) 2012-06-19 2015-08-21 Polytherics Ltd
CN110201186A (zh) * 2012-10-23 2019-09-06 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
NO2789793T3 (fr) 2012-10-24 2018-01-27
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
US10570151B2 (en) * 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CN103254311B (zh) 2013-05-09 2015-05-13 齐鲁制药有限公司 一种制备抗体-美登素类生物碱药物偶联物的方法
WO2014194030A2 (fr) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
EP3003390B1 (fr) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anticorps anti-c10orf54 et leurs utilisations
WO2014197866A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps modifiés et composés associés, compositions et procédés d'utilisation
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015031396A1 (fr) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des diastéréomères macrolides, leurs procédés de synthèse et leurs utilisations thérapeutiques
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9562059B2 (en) 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
CA2950155C (fr) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Conjugues de molecules biologiquement actives, reactifs et methodes de fabrication, et utilisations therapeutiques
EP3273998B1 (fr) 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
MX2019003325A (es) 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
MA43094B1 (fr) 2020-10-28
US20200121806A1 (en) 2020-04-23
AU2017211120C1 (en) 2021-10-07
US20230116771A1 (en) 2023-04-13
PH12018501589A1 (en) 2019-04-08
EA039072B9 (ru) 2022-02-04
CN108779127B (zh) 2022-07-05
AU2017211120A1 (en) 2018-07-26
MY198605A (en) 2023-09-08
AU2017211120B2 (en) 2021-04-01
EP3408271B1 (fr) 2023-01-11
CN108779127A (zh) 2018-11-09
EA039072B1 (ru) 2021-11-30
EA201800444A1 (ru) 2019-04-30
WO2017132173A1 (fr) 2017-08-03
US10463749B2 (en) 2019-11-05
CN114478801A (zh) 2022-05-13
US9950076B2 (en) 2018-04-24
ZA201804593B (en) 2022-12-21
CO2018008761A2 (es) 2018-10-22
EP3408271A1 (fr) 2018-12-05
US20180289834A1 (en) 2018-10-11
MX2018008987A (es) 2018-11-19
BR112018014759A2 (pt) 2018-12-11
IL260744B (en) 2021-03-25
CL2018002012A1 (es) 2018-08-31
US20170209591A1 (en) 2017-07-27
JP6934010B2 (ja) 2021-09-08
CA3011440A1 (fr) 2017-08-03
US11446389B2 (en) 2022-09-20
BR112018014759B1 (pt) 2024-02-27
MA43094A1 (fr) 2019-06-28
JP2019502746A (ja) 2019-01-31
KR20180099892A (ko) 2018-09-05
HK1257219A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201809554VA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201900665VA (en) Cannabis composition
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds